Breast-Conserving Therapy is Associated with Improved Survival Compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database
»
Breast-Conserving Therapy is Associated with Improved Survival Compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database
Introduction: The current recommendation for early-stage breast cancer is largely based on the NSABP B-06 trial showed similar survival between mastectomy and lumpectomy. We sought to compare breast conservation therapy (BCT) with mastectomy for early stage breast cancer treatment in a patient population contemporary.
Methods: A query of NCDB PUF identified female breast cancer patients diagnosed from 2004 to 2015. Patients with stage I or II disease were included. BCT was defined as receipt of lumpectomy plus radiation. propensity score tabulated using race, age, score Charlson / Deyo, tumor location, laterality, histology, grade, size, number of positive nodes, lymph-vascular invasion, receptor status, receiving chemotherapy and endocrine therapy.
Patients who received BCT compared to mastectomy matched using 1: 1 nearest neighbor technique. The main outcome measure was overall survival. Results: After exclusions and matching, two equal groups of 101 118 patients remained. Median follow-up was 42 months. The majority had invasive ductal histology (77%), and node-negative disease (84%). receptor status, including ER-positive (83%), PR-positive (73%), and HER2 / Neu positive (15%). 38% received chemotherapy and endocrine therapy in 71%.
Propensity score matching produce similar groups in all target variables. 5-year overall survival is superior to the BCT compared with mastectomy (92.9% vs 89.7%, p <0.001 ;. Figure 1). This survival advantage to survive for both phase I (p <0.001) and stage II (p <0.001) disease in the subgroup analysis. Picture. 1 overall survival in female patients with early stage invasive breast cancer (stage I or II) who underwent breast-conserving surgery with radiation compared to mastectomy. CONCLUSION BCS breast conserving surgery: BCT associated with superior overall survival compared to mastectomy for early stage breast cancer using a suitable, contemporary data.
Breast-Conserving Therapy is Associated with Improved Survival Compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database
Tomosynthesis mammography Imaging Screening Trial (TMIST): An Invitation and Opportunities for Communities National Medical Association to Shape the Future of Precision Screening for Breast Cancer
To determine the best screening modalities for breast cancer, a large randomized clinical trial is underway to compare the accuracy of mammography between standard digital mammography and tomosynthesis. The tomosynthesis mammography Imaging Screening Trial (TMIST) also built the world’s largest biorepository breast cancer specimens of all biopsy at screening and want to ensure it is representative of the US population.
We invite doctors of the National Medical Association, as a leader in the African American health care, to continue their commitment to eliminate the gap by promoting TMIST among African American women. The results of the trial will help to advance screening precision, individually adjust the screening decision is based on breast density, tumor subtyping and genomics. The partnership with the NMA is important to build confidence, dispel misunderstandings about clinical trials in the community as well as to support a cadre of African American physicians and researchers who can contribute to the current understanding of the social factors of breast cancer.
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human CGA / hCG Alpha . This antibody is tested and proven to work in the following applications:
Description: Tumor necrosis factor alpha (TNFSF2, TNF alpha) is a member of the TNF Superfamily. TNF alpha, being an endogenous pyrogen, is able to induce fever, to induce apoptotic cell death, to induce sepsis (through IL-1 & IL-6 production), to induce cachexia, induce inflammation, and to inhibit tumorigenesis and viral replication. Canine TNF alpha Recombinant Protein is purified TNF alpha (TNFSF2) produced in yeast.
Description: IL-1α is a non-secreted proinflammatory cytokine produced in a variety of cells including monocytes, tissue macrophages, keratinocytes and other epithelial cells. Both IL-1α and IL-1β binds to the same receptor and has similar if not identical biological properties. These cytokines have a broad range of activities including, stimulation of thymocyte proliferation, by inducing IL-2 release, B-cell maturation and proliferation, mitogenic FGF-like activity and the ability to stimulate the release of prostaglandin and collagenase from synovial cells. However, whereas IL-1β is a secreted cytokine, IL-1α is predominantly a cell-associated cytokine. Recombinant human IL-1α is an 18.0 kDa protein containing 159 amino acid residues.
Description: IL-1 alpha (IL-1α, IL-1F1) is a member of the interleukin 1 family of cytokines. IL-1 alpha is an inflammatory cytokine active in the initiation of the inflammatory reaction and in driving Th1 and Th17 inflammatory responses. Equine IL-1 alpha Recombinant Protein is purified interleukin-1 alpha cytokine produced in yeast.
Description: IFN alpha is a mammalian Type I inferferon, mainly involved in innate immune response against viral infection. Equine IFN alpha 1 Recombinant Protein is purified IFN alpha produced in yeast.
Description: The recognized V5 epitope represents 95GKPIPNPLLGLDST108 of RNA polymerase ? subunit of simian parain?uenza virus type 5. This short peptide sequence was chosen because high-af?nity antibodies can be reliably produced in many different species1.
Description: The recognized V5 epitope represents 95GKPIPNPLLGLDST108 of RNA polymerase ? subunit of simian parain?uenza virus type 5. This short peptide sequence was chosen because high-af?nity antibodies can be reliably produced in many different species1.
Description: SDF-1α and β are stromal derived CXC chemokines, and signal through the CXCR4 receptor. SDF-1α and β chemoattract B and T cells, and have been shown to induce migration of CD34+ stem cells. Additionally, the SDF-1 proteins exert HIV suppressive activity in cells expressing the CXCR4 receptor. Recombinant murine SDF-1α is a 7.9 kDa protein containing 68 amino acid residues.
Anti-Alpha Internexin INA Intermediate Neurofilament Antibody
Description: Chicken Polyclonal Alpha Internexin INA Intermediate Neurofilament Antibody. Validated in IF, IHC, WB and tested in Bovine, Equine, Human, Mouse, Pig, Rat.
Description: A-Synuclein Delta-NAC Human Recombinant which is a deletion mutant of the a-synuclein that lacks the NAC region (amino acid 61-95), produced in E.Coli is a single, non-glycosylated polypeptide chain of 111 amino acids having a molecular mass of 11.9kDa (molecular size on SDS-PAGE will appear higher), with 6 amino acids added as a linker. The Recombinant Human a-Synuclein Delta-NAC is purified by proprietary chromatographic techniques.
Description: 800x600 EPO a Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 189 amino acids (28-193a.a.) and having a molecular mass of 20.9kDa.;EPO a is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Description: Interferon-alpha 2b Human Recombinant produced in yeast is a single, glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of approximately 19 kDa.;The Interferon-alpha 2b gene was obtained from human leukocytes.;The IFN-a 2b is purified by proprietary chromatographic techniques.
In this retrospective study, we included newly diagnosed patients from 2004 to 2010. The study included 9266 patients with breast cancer who were enrolled in the treatment MDT and 9266 patients who did not. This study using the log-rank test to analyze the characteristics of patients, hospital characteristics, cancer staging and treatment methods to compare the recurrence rate in the treatment of non-MDT and MDT treatment of participants. We used Cox proportional hazards model to test the effect of MDT and related factors on the risk of recurrence and death from breast cancer patients.
